Ciccaglione AF, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L (2016) Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: two pilot studies
GLP-1 therapies are moving beyond diabetes and obesity into MASH/NAFLD, cardiovascular risk reduction, and possibly neurodegenerative conditions
Constipation occurs because prolonged colonic transit time increases water absorption from stools, making them harder and more difficult to pass
Our BPC-157 therapy focuses on: Enhanced joint and muscle recovery Gut and systemic healing Autoimmune and inflammatory balance Long-term performance and cellular health Each program is doctor-supervised and based on evidence-based regenerative protocols to ensure safety and results
Disulphide bond integrity: Uniquely important for this compound, the disulphide bond between Cys-7 and Cys-15 must be correctly formed